Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

NEW YORK — Abbott said on Friday that it has received Emergency Use Authorization from the US Food and Drug Administration for a PCR-based assay that can detect and differentiate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus.

The newly authorized Alinity m Resp-4-Plex assay, which is also CE marked, uses a single anterior nasal or nasopharyngeal swab sample collected by a healthcare provider or self-collected at a healthcare facility, according to Abbott. It runs on the company's Alinity m system.

Abbott also said that the previously granted EUA for its Alinity m SARS-CoV-2 test has been updated to include its use with asymptomatic individuals, as well as with pooled samples.

That test was first authorized by the FDA in December for detecting SARS-CoV-2 nucleic acid in nasal, nasopharyngeal, and oropharyngeal swabs, as well as bronchoalveolar lavage specimens, collected from individuals suspected of having COVID-19.

According to Abbott Park, Illinois-based Abbott, that EUA has now been expanded to allow the test's use with people not showing symptoms of infection and with up to five samples at a time.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.